The utility of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele
Key studies on multiple myeloma presented at ASH 2016
The role of patients and patient groups in the European Reference Network EuroBloodNet
Joan Lluis Vives-Corrons et al.
Second-line myelofibrosis treatment – the potential of JAK2 inhibitor NS-018
From Structure to Function to Clinical Outcome